Phase 2 Study of VE303 for Prevention of Recurrent Clostridioides Difficile Infection

NCT03788434 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

79

Enrollment

INDUSTRY

Sponsor class

Conditions

Clostridium Difficile Infection Recurrence
Clostridium Difficile Infection
Clostridium Difficile
Clostridioides Difficile Infection Recurrence
Clostridioides Difficile Infection
Clostridioides Difficile
CDI

Interventions

DRUG: VE303
DRUG: Placebo

Sponsor

Vedanta Biosciences, Inc.